CG Oncology, Inc. Common stock
Symbol: CGON (NASDAQ)
39.49
▼ (-1.97%) -0.795
Company Description:
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Key Stats
- Today's Open: $40.03
- Today's High: $41.385
- Today's Low: $38.371
- Today's Volume: 1.13M
- Yesterday Close: $40.28
- Yesterday High: $40.53
- Yesterday Low: $38.63
- Yesterday Volume: 752.17K
- Last Min Volume: 1
- Last Min High: $39.485
- Last Min Low: $39.485
- Last Min VWAP: $39.485
Company Profile
- Name: CG Oncology, Inc. Common stock
- Website: https://www.cgoncology.com
- Listed Date: 2024-01-25
- Location: IRVINE, CA
- Market Status: Active
- CIK Number: 0001991792
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $3.07B
- Round Lot: 100
- Outstanding Shares: 76.25M
- Asset Type: CS
RECENT FILINGS FOR CGON
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-01 | 4 | View |
| 2025-09-30 | 4 | View |
| 2025-09-30 | 144 | View |
| 2025-09-22 | 4 | View |
| 2025-09-18 | SCHEDULE 13D | View |
| 2025-09-18 | SCHEDULE 13D | View |
| 2025-09-18 | 144 | View |
| 2025-09-16 | 4 | View |
| 2025-09-15 | 144 | View |
| 2025-09-15 | 4 | View |
| 2025-09-09 | 8-K | View |
| 2025-09-08 | 4 | View |
| 2025-09-05 | 144 | View |
| 2025-09-05 | 8-K | View |
| 2025-09-04 | 4 | View |
| 2025-09-04 | 4 | View |
| 2025-09-03 | 144 | View |
| 2025-09-03 | 144 | View |
| 2025-08-08 | 10-Q | View |
| 2025-08-08 | 8-K | View |
Latest News on CGON